RATIO-PRAVASTATIN TABLET

国: カナダ

言語: 英語

ソース: Health Canada

有効成分:

PRAVASTATIN SODIUM

から入手可能:

RATIOPHARM INC DIVISION OF TEVA CANADA LIMITED

ATCコード:

C10AA03

INN（国際名）:

PRAVASTATIN

投薬量:

40MG

医薬品形態:

TABLET

構図:

PRAVASTATIN SODIUM 40MG

投与経路:

ORAL

パッケージ内のユニット:

30/100

処方タイプ:

Prescription

治療領域:

HMG-COA REDUCTASE INHIBITORS

製品概要:

Active ingredient group (AIG) number: 0122563003; AHFS:

認証ステータス:

CANCELLED POST MARKET

承認日:

2014-09-19

製品の特徴

Product Monograph – ratio-PRAVASTATIN
Page 1 of 40
PRODUCT MONOGRAPH
PR
RATIO-PRAVASTATIN
PRAVASTATIN SODIUM
10, 20 AND 40 MG TABLETS
LIPID METABOLISM REGULATOR
_ _
_ _
_ _
_ _
RATIOPHARM INC.
17 800 Lapointe
Mirabel, Quebec
Canada, J7J 1P3
Date of Revision:
April 12, 2011
Submission Control No: 145497
Product Monograph – ratio-PRAVASTATIN
Page 2 of 40
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.........................................................3
SUMMARY PRODUCT
INFORMATION.......................................................................................
3
INDICATIONS AND CLINICAL
USE.............................................................................................
3
CONTRAINDICATIONS
....................................................................................................................
5
ADVERSE
REACTIONS..................................................................................................................11
DRUG
INTERACTIONS...................................................................................................................15
OVERDOSAGE
.................................................................................................................................
17
ACTION AND CLINICAL
PHARMACOLOGY..........................................................................18
STORAGE AND
STABILITY..........................................................................................................20
DOSAGE FORMS, COMPOSITION AND PACKAGING
.........................................................20
PART II: SCIENTIFIC INFORMATION
................................................................................21
CLINICAL
TRIALS...........................................................................................................................22
DETAILED
PHARMACOLOGY....................................................................................................27
REFERENCES....................................................